Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention
ConclusionThis study identified possible PCa tumor markers to more accurately predict the occurrence, progression, and prognosis of PCa, and which could be used in the development of tumor drug therapy.
Publication date: Available online 22 May 2019Source: Pathology - Research and PracticeAuthor(s): Song Wan, Ming Xi, Hai-Bo Zhao, Wei Hua, Yuan-Ling Liu, Yu-Lin Zhou, Yang-Jia Zhuo, Ze-Zhen Liu, Zhi-Duan Cai, Yue-Ping Wan, Wei-De ZhongAbstractBackgroundAccumulating studies reported that 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) may function as either an oncogene or a tumor suppressor in various human cancers. However, its involvement in prostate cancer (PCa) remains unknown. Therefore, the aim of this study was to investigate the clinical significance of HMGCS2 expression and its functions in PCa.MethodsExpression...
Authors: Xu SG, Yu JJ, Shi Q, Niu Q, Guo Z, Guo BY, Zhou GC, Gu X, Wu YX Abstract The present study aimed to construct conditionally replicative adenovirus (CRAds) carrying small hairpin (sh)RNA targeting enhancer of zeste homolog 2 (EZH2), in order to study its effect on inhibiting prostate cancer (PCa) cell growth and invasion. Immunohistochemical analyses of EZH2 was performed in tumor tissue samples from PCa and benign prostate hyperplasia (BPH). The human telomerase reverse transcriptase (hTERT) promoter was chosen to transcriptionally control EZH2 gene expression to obtain adenoviral replication (Adâ€‘hTERTâ€...
Differential gene methylation patterns in cancerous and nonâ€‘cancerous cells. Oncol Rep. 2019 May 15;: Authors: KamiĹ„ska K, BiaĹ‚kowska A, Kowalewski J, Huang S, Lewandowska MA Abstract Largeâ€‘scale projects, such as The Cancer Genome Atlas (TCGA), Human Epigenome Project (HEP) and Human Epigenome Atlas (HEA), provide an insight into DNA methylation and histone modification markers. Changes in the epigenome significantly contribute to the initiation and progression of cancer. The goal of the present study was to characterize the prostate cancer malignant transformation model using the CpG island met...
Authors: Mohler JL, Antonarakis ES Abstract Updates to the NCCN Guidelines for Prostate Cancer include further refinements in taking a family history, new recommendations for germline and somatic testing, use of androgen receptor blockers for nonmetastatic castration-resistant prostate cancer, advice regarding intermittent versus continuous androgen deprivation therapy, and consideration of whether to treat the primary tumor in men diagnosed with de novo metastatic prostate cancer. PMID: 31117038 [PubMed - in process]
Condition: Prostate Cancer Intervention: Procedure: prostate biopsies Sponsor: Institut Cancerologie de l'Ouest Recruiting
Condition: Prostatic Neoplasms Intervention: Radiation: stereotactic mr guided adaptive radiotherapy Sponsor: VU University Medical Center Completed
Conditions: Cancer of the Prostate; Castration-resistant Prostate Cancer Intervention: Drug: Gadoxetate Sodium Sponsor: University of Cincinnati Recruiting
Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Conclusion: Our results suggest that multiple genes and pathways may play key roles in TP53 mutant prostate cancer, providing candidate targets and strategies for individualized treatment. PMID: 31116024 [PubMed - as supplied by publisher]
CONCLUSION: The knowledge of difference in bio-distribution between two tracers may help in interpretation of PET data. Diagnostic pitfalls can be documented, due to the possibility of PSMA uptake in inflammation. Our results are preliminary to future studies comparing diagnostic accuracies of 68Ga-PSMA and 64Cu-PSMA. PMID: 31113354 [PubMed - as supplied by publisher]